+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) - Market Insight, Epidemiology and Market Forecast -2032

  • ID: 5025136
  • Report
  • January 2022
  • Region: Global
  • 200 Pages
  • DelveInsight

FEATURED COMPANIES

  • Hoffmann-La Roche
  • Takeda Pharmaceuticals
  • Xcovery
This "Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC), historical and forecasted epidemiology as well as the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market report provides current treatment practices, emerging drugs, Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market share of the individual therapies, current and forecasted Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Disease Understanding and Treatment Algorithm


The Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market report gives a thorough understanding of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis


This segment of the report covers the detailed diagnostic methods or tests for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC).

Treatment


It covers the details of conventional and current medical therapies available in the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market for the treatment of the condition. It also provides Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) treatment algorithms and guidelines in the United States, Europe, and Japan.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology


The Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) epidemiology division provide insights about historical and current Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings


The disease epidemiology covered in the report provides historical as well as forecasted Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology


The epidemiology segment also provides the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Drug Chapters


Drug chapter segment of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) report encloses the detailed analysis of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs


The report provides the details of the marketed product available for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) treatment.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Emerging Drugs


The report provides the details of the emerging therapies under the late and mid-stage of development for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) treatment.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Market Outlook


The Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market in 7MM is expected to change in the study period 2019-2032.

Key Findings


This section includes a glimpse of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market in 7MM.

The United States Market Outlook


This section provides the total Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook


The total Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook


The total Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market size and market size by therapies in Japan is also mentioned.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Drugs Uptake


This section focusses on the rate of uptake of the potential drugs recently launched in the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market or expected to get launched in the market during the study period 2019-2032. The analysis covers Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Pipeline Development Activities


The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) key players involved in developing targeted therapeutics.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) emerging therapies.

Reimbursement Scenario in Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)


Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL-Views


To keep up with current market trends, we take KOLs and SME's opinion working in Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis


The publisher performs Competitive and Market Intelligence analysis of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market

Report Highlights

  • In the coming years, Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC). Launch of emerging therapies will significantly impact the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Pipeline Analysis
  • Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Report Assessment


Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions Answered


Market Insights:

  • What was the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market size during the forecast period (2019-2032)?
  • At what CAGR, the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market is expected to grow in 7MM during the forecast period (2019-2032)?
  • What would be the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)?
  • What is the historical Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) during the forecast period (2019-2032)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) in the USA, Europe, and Japan?
  • What are the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)?
  • How many therapies are developed by each company for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) and their status?
  • What are the key designations that have been granted for the emerging therapies for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)?
  • What are the global historical and forecasted market of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)?

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market
  • To understand the future market competition in the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market
  • To understand the future market competition in the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) market
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Hoffmann-La Roche
  • Takeda Pharmaceuticals
  • Xcovery

1. Key Insights2. Executive Summary of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)3. Competitive Intelligence Analysis for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)
4. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC): Market Overview at a Glance
4.1. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Total Market Share (%) Distribution in 2019
4.2. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Total Market Share (%) Distribution in 2032
5. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC): Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology Scenario in the 7MM (2019-2032)
7.4. United States Epidemiology
7.4.1. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology Scenario in the United States (2019-2032)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology Scenario in Germany (2019-2032)
7.5.2. France Epidemiology
7.5.2.1. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology Scenario in France (2019-2032)
7.5.3. Italy Epidemiology
7.5.3.1. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology Scenario in Italy (2019-2032)
7.5.4. Spain Epidemiology
7.5.4.1. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology Scenario in Spain (2019-2032)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology Scenario in the United Kingdom (2019-2032)
7.5.6. Japan Epidemiology
7.5.6.1. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology Scenario in Japan (2019-2032)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Treatment and Management
8.2. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Treatment Algorithm
9. Unmet Needs10. Key Endpoints of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC): Seven Major Market Analysis
13.1. Key Findings
13.2. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Market Size in 7MM
13.3. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Total Market Size in the United States
15.1.2. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Total Market Size in Germany
15.3.2. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Total Market Size in France
15.4.2. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Total Market Size in Italy
15.5.2. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Total Market Size in Spain
15.6.2. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Total Market Size in the United Kingdom
15.7.2. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Total Market Size in Japan
15.8.3. Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)17. KOL Views18. Market Drivers19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. Publisher Capabilities22. Disclaimer
23. About the Publisher
*The table of contents is not exhaustive; the final content may vary.
List of Tables
Table 1: 7MM Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology (2019-2032)
Table 2: 7MM Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Diagnosed and Treatable Cases (2019-2032)
Table 3: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology in the United States (2019-2032)
Table 4: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology in Germany (2019-2032)
Table 6: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology in France (2019-2032)
Table 8: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology in Italy (2019-2032)
Table 10: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology in Spain (2019-2032)
Table 12: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology in the UK (2019-2032)
Table 14: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Diagnosed and Treatable Cases in the UK (2019-2032)
Table 15: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology in Japan (2019-2032)
Table 16: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Diagnosed and Treatable Cases in Japan (2019-2032)
Table 17: Drug Name, Clinical Trials by Recruitment status
Table 18: Drug Name, Clinical Trials by Zone
Table 19: Total Seven Major Market Size in USD, Million (2019-2032)
Table 20: Region-wise Market Size in USD, Million (2019-2032)
Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
Table 22: United States Market Size in USD, Million (2019-2032)
Table 23: United States Market Size by Therapy in USD, Million (2019-2032)
Table 24: Germany Market Size in USD, Million (2019-2032)
Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)
Table 26: France Market Size in USD, Million (2019-2032)
Table 27: France Market Size by Therapy in USD, Million (2019-2032)
Table 28: Italy Market Size in USD, Million (2019-2032)
Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)
Table 30: Spain Market Size in USD, Million (2019-2032)
Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)
Table 32: United Kingdom Market Size in USD, Million (2019-2032)
Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
Table 34: Japan Market Size in USD, Million (2019-2032)
Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)
*The list of tables is not exhaustive; the final content may vary
List of Figures
Figure 1: 7MM Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology (2019-2032)
Figure 2: 7MM Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Diagnosed and Treatable Cases (2019-2032)
Figure 3: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology in the United States (2019-2032)
Figure 4: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology in Germany (2019-2032)
Figure 6: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology in France (2019-2032)
Figure 8: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology in Italy (2019-2032)
Figure 10: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology in Spain (2019-2032)
Figure 12: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology in the UK (2019-2032)
Figure 14: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Diagnosed and Treatable Cases in the UK (2019-2032)
Figure 15: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology in Japan (2019-2032)
Figure 16: Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Diagnosed and Treatable Cases in Japan (2019-2032)
Figure 17: Drug Name, Clinical Trials by Recruitment status
Figure 18: Drug Name, Clinical Trials by Zone
Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)
Figure 20: Region-wise Market Size in USD, Million (2019-2032)
Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
Figure 22: United States Market Size in USD, Million (2019-2032)
Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)
Figure 24: Germany Market Size in USD, Million (2019-2032)
Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)
Figure 26: France Market Size in USD, Million (2019-2032)
Figure 27: France Market Size by Therapy in USD, Million (2019-2032)
Figure 28: Italy Market Size in USD, Million (2019-2032)
Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)
Figure 30: Spain Market Size in USD, Million (2019-2032)
Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)
Figure 32: United Kingdom Market Size in USD, Million (2019-2032)
Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
Figure 34: Japan Market Size in USD, Million (2019-2032)
Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)
*The list of figures is not exhaustive; the final content may vary
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Hoffmann-La Roche
  • Takeda Pharmaceuticals
  • Xcovery

Country Wise- Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Epidemiology

Estimates show the highest Incident population of ALK NSCLC is in the United States. Furthermore, among the European 5 countries, the Germany had highest incident population of NSCLC.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Drug Chapters

Drug chapter segment of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer report encloses the detailed analysis of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Marketed Drugs

Xalkori (Crizotinib): Pfizer
Xalkori (Crizotinib), an ALK inhibitor, was first-ever approved treatment for metastatic NSCLC by the US FDA. This product received accelerated approval in 2011. The US FDA approval of Xalkori is based on data from 255 patients with locally advanced or metastatic ALK-positive NSCLC across two multicenter, single-arm studies, including a Phase II study (PROFILE 1005) and a Part 2 expansion cohort of a Phase I study (Study 1001).

Alunbrig (Brigatinib): Takeda
Alunbrig (Brigatinib) was approved by the US FDA in April 2017 for the treatment of patients with ALK+ metastatic NSCLC who have progressed on or are intolerant to Crizotinib. In the year 2018, the European Commission (EC) also granted marketing authorization for Alunbrig as a monotherapy for the treatment of adult patients with ALK+ NSCLC previously treated with Crizotinib. In April 2020, the European Commission (EC) extended the current marketing authorization of Alunbrig to include use as a monotherapy for the treatment of adult patients with ALK+ advanced NSCLC previously not treated with an ALK inhibitor. This decision came after a positive opinion from the CHMP on February 27, 2020.

Products detail in the report.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Emerging Drugs

Ensartinib: Xcovery Holding Company
Xcovery is investigating their drug candidate, Ensartinib which is a potential best-in-class oral compound for the first-line treatment of ALK-positive NSCLC. This product has additional activity against MET, ABL, Axl, EPHA2, LTK, ROS1, and SLK. In phase I/II clinical trial, this product has shown promising activity in both ALK TKI naïve and crizotinib-resistant ALK+ NSCLC patients. Ensartinib is generally well tolerated with the most common toxicities being rash and nausea/vomiting, the latter often resolved with food.

At present, a global Phase III clinical trial (eXalt3) is ongoing comparing Ensartinib to Crizotinib in TKI naïve ALK-positive NSCLC patient. The primary purpose of this study is to evaluate the efficacy and safety of ensartinib vs. crizotinib in patients with ALK-positive NSCLC that have received up to one prior chemotherapy regimen and no prior ALK inhibitor.

Products detail in the report.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market Outlook

Key Findings

According to the publisher, Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market in the 7MM is expected to change in the study period 2017-2030. The therapeutic market of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer in seven major markets was found to be USD 841 million in 2017 which is expected to increase during study period (2017-2030).

The United States Market Outlook

In 2017, the total market size of ALK NSCLC therapies was found to be USD 422 million in the United States which is expected to increase in the study period (2017-2030).

EU-5 Countries: Market Outlook

In 2017, the total market size of ALK NSCLC therapies was found to be USD 267 million in the EU-5 countries which is expected to increase in the study period (2017-2030).

Japan Market Outlook

The total market size of ALK NSCLC therapies in Japan was found to be USD 152 million in 2017.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Pipeline Development Activities

The drugs which are in pipeline includes:
1. Ensartinib: Xcovery Holding Company: Phase III

Products detail in the report.

Pipeline Development Activities

Key Points

1. At present, a global Phase III clinical trial (eXalt3) is ongoing comparing Ensartinib to Crizotinib in TKI naïve ALK-positive NSCLC patient. The primary purpose of this study is to evaluate the efficacy and safety of ensartinib vs. crizotinib in patients with ALK-positive NSCLC that have received up to one prior chemotherapy regimen and no prior ALK inhibitor.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Drugs Uptake

The current market is dominated by Alecensa (alectinib) which is expected to generate its peak revenue in coming years, and after that its revenue is expected to decline. This decline is a majorly attributed due to the presence of Lorbrena (because it is targeting the patient pool which is refractory to Crizotinib, Alectinib, and Ceritinib.

Access and Reimbursement Scenario in Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Therapies


  • In 2018, Alecensa was recommended, within its marketing authorization, for untreated patients with NSCLC, whose tumors are identified as ALK-positive. Alecensa demonstrated considerable improvements in delaying cancer growth in enrolled patients. It has also shown significant improvements in preventing and delaying cancer spread into the brain.
  • This decision was entirely based on data from the Phase III ALEX study, which showed a reduction in the risk of disease worsening, or death by 57% compared with standard of care Xalkori.

KOL - Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Anaplastic lymphoma kinase Non-Small Cell Lung Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report


  • The report covers the descriptive overview of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • Comprehensive insight has been provided into the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market.

Report Highlights


  • In the coming years, Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Anaplastic lymphoma kinase Non-Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer. Launch of emerging therapies, will significantly impact the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Report Insights


  • Patient Population
  • Therapeutic Approaches
  • Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Pipeline Analysis
  • Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Report Key Strengths


  • 11 Years Forecast
  • 7MM Coverage

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Epidemiology Segmentation


  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Report Assessment


  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Conjoint Analysis
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions Answered

Market Insights:


  • What was the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer total market Size as well as market size by therapies across the 7MM during the study period (2017-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market size during the study period (2017-2030)?
  • At what CAGR, the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market is expected to grow in the 7MM during the study period (2017-2030)?
  • What would be the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market outlook across the 7MM during the study period (2017-2030)?
  • What would be the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
  • Anaplastic lymphoma kinase Non-Small Cell Lung Cancer patient types/ pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies based on their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market?

Epidemiology Insights:


  • What is the disease risk, burden and unmet needs of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?
  • What is the historical Anaplastic lymphoma kinase Non-Small Cell Lung Cancer patient pool in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What would be the forecasted patient pool of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer in 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?
  • Out of all the 7MM countries, which country would have the highest Incident population of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer during the study period (2017-2030)?
  • At what CAGR the population is expected to grow in the 7MM during the study period (2017-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:


  • What are the current options for the treatment of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer in the US, Europe and Japan?
  • What are the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?
  • How many therapies are developed by each company for the treatment of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?
  • How many emerging therapies are in mid stage, and late stage of development for the treatment of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer and their status?
  • What are the key designations that have been granted for the emerging therapies for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?
  • What are the global historical and forecasted market of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?

Reasons to buy


  • The report will help in developing business strategies by understanding trends shaping and driving the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market.
  • To understand the future market competition in the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market.
  • To understand the future market competition in the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Hoffmann-La Roche
  • Takeda Pharmaceuticals
  • Xcovery
Note: Product cover images may vary from those shown